Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Radiopharm Theranostics Ltd banner
R

Radiopharm Theranostics Ltd
ASX:RAD

Watchlist Manager
Radiopharm Theranostics Ltd
ASX:RAD
Watchlist
Price: 0.009 AUD -10% Market Closed
Market Cap: AU$35.4m
Write Note Create Alert Ask AI

Wall St Price Targets

RAD Price Targets Summary
Radiopharm Theranostics Ltd

Wall Street analysts forecast RAD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RAD is 0.061 AUD with a low forecast of 0.061 AUD and a high forecast of 0.063 AUD.

RAD Lowest Forecast
Wall Street Target
AU$0.061
573% Upside
RAD Average Forecast
Wall Street Target
AU$0.061
580% Upside
RAD Highest Forecast
Wall Street Target
AU$0.063
600% Upside
Lowest Forecast
Price Target
0.061 AUD
573% Upside
Average Forecast
Price Target
0.061 AUD
580% Upside
Highest Forecast
Price Target
0.063 AUD
600% Upside
Radiopharm Theranostics Ltd Competitors:
Price Targets
EBS
Emergent BioSolutions Inc
87% Upside
CENT
Central Garden & Pet Co
20% Upside
NCSM
NCS Multistage Holdings Inc
38% Upside
SSTI
Shotspotter Inc
45% Upside
EBS
Emergent BioSolutions Inc
87% Upside
CENT
Central Garden & Pet Co
20% Upside
NCSM
NCS Multistage Holdings Inc
38% Upside
SSTI
Shotspotter Inc
45% Upside
CASY
Caseys General Stores Inc
29% Upside
H
HUBC
Hub Power Company Ltd
2% Upside
T
TRIN
Trinity Capital Inc
0% Downside

Revenue
Forecast

N/A
Past Growth
93% / Year
Estimated Growth
Estimates Accuracy
45%
Average Beat
N/A
Past Growth
93% / Year
Estimated Growth
Estimates Accuracy
45%
Average Beat

The compound annual growth rate for Revenue over the next 8 years is 93%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
234% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
234% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

The compound annual growth rate for Gross Profit over the next 8 years is 234%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
8%
Average Beat

What are analyst estimates?

Continue RAD Research

Summary
RAD intrinsic value, competitors valuation, and company profile.
DCF Valuation
RAD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RAD stock valuation using valuation multiples.
Wall St Estimates
RAD price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RAD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Radiopharm Theranostics Ltd listings:
OTC • USD
RDPTF
 NASDAQ • USD
RADX
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RAD's stock price target?
Price Target
0.061 AUD

According to Wall Street analysts, the average 1-year price target for RAD is 0.061 AUD with a low forecast of 0.061 AUD and a high forecast of 0.063 AUD.

What is the Revenue forecast for Radiopharm Theranostics Ltd?
Projected CAGR
93%

The compound annual growth rate for Revenue over the next 8 years is 93%.

What is the Gross Profit forecast for Radiopharm Theranostics Ltd?
Projected CAGR
234%

The compound annual growth rate for Gross Profit over the next 8 years is 234%.

Back to Top
ALPHA SPREAD
Follow us
Join 355,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett